高通量测序在肝硬化患者腹水、血清及粪便微生物群检测中的应用

李真; 张维; 贾琳; 胡中杰

doi:10.3969/j.issn.1001-5256.2020.04.042

高通量测序在肝硬化患者腹水、血清及粪便微生物群检测中的应用

DOI: 10.3969/j.issn.1001-5256.2020.04.042

首都医科大学附属北京佑安医院肝病重症医学科

基金项目:

中国初级保健基金会佑安肝病艾滋病基金(2017003)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 775
- HTML全文浏览量: 23
- PDF下载量: 167
- 被引次数: 0
出版历程
- 出版日期: 2020-04-20

Advances in the clinical application of high-throughput sequencing in detecting microbiota in cirrhotic ascites,serum,and feces

Department of Severe Liver Disease, Beijing YouAn Hospital, Capital Medical University

Research funding:

摘要

摘要: 肝硬化是慢性进展性肝病,且肝硬化患者极易发生感染,尤其腹水、血清、粪便的菌群变化与肝硬化的进展及并发症有关。但是,大多数患者因腹水、血液中的细菌丰度低无法进行有效的细菌培养,因此难以进行全面分析。二代测序技术的高通量和高速度优势可以用于病原体生物学及临床诊断,包括病原体检测和鉴定、菌株分型、微生物组学研究,从而帮助临床医师优化抗菌药物的使用。目前,二代测序技术不断成熟,临床上对微生物群的全基因组进行分析成为可能。
- 肝硬化 /
- 序列分析,DNA /
- 微生物群
Abstract: Liver cirrhosis is a chronic progressive liver disease,and patients with liver cirrhosis are highly susceptible to infection. The changes in microbiota in ascites,serum,and feces are associated with the progression and complications of liver cirrhosis. However,effective bacterial culture cannot be performed for most patients due to low bacterial abundance in ascites and blood,and thus it is difficult to conduct a comprehensive analysis. The high-throughput and high-speed advantages of next-generation sequencing technique can be used for pathogen biology and clinical diagnosis,including pathogen detection and identification,strain typing,and microbiome studies,to help clinicians optimize the application of antimicrobials. At present,the next-generation sequencing technique gradually becomes mature,making it possible to analyze the whole genome of microbiota.
- liver cirrhosis /
- sequence analysis,DNA /
- microbiota

HTML全文

参考文献(35)

[1] WOO PC,LAU SK,TENG JL,et al. Then and now:Use of16S r DNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories[J]. Clin Microbiol Infect,2008,14(10):908-934.

[2] NOBRE SR,CABRAL JE,GOMES JJ,et al. In-hospital mortality in spontaneous bacterial peritonitis:A new predictive model[J].Eur J Gastroenterol Hepatol,2008,20(12):1176-1181.

[3] ENGELMANN C,KROHN S,PRYWEREK D,et al. Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival[J]. Eur J Gastroenterol Hepatol,2016,28(11):1285-1292.

[4] HARDICK J,WON H,JENG K,et al. Identification of bacterial pathogens in ascitic fluids from patients with suspected spontaneous bacterial peritonitis by use of broad-range PCR(16S PCR)coupled with high-resolution melt analysis[J]. J Clin Microbiol,2012,50(7):2428-2432.

[5] LUTZ P,NISCHALKE HD,STRASSBURG CP,et al. Spontaneous bacterial peritonitis:The clinical challenge of a leaky gut and a cirrhotic liver[J]. World J Hepatol,2015,7(3):304-314.

[6] MINEMURA M,SHIMIZU Y. Gut microbiota and liver diseases[J]. World J Gastroenterol,2015,21(6):1691-1702.

[7] MARCHESI JR,ADAMS DH,FAVA F,et al. The gut microbiota and host health:A new clinical frontier[J]. Gut,2016,65(2):330-339.

[8] GOEL A,GUPTA M,AGGARWAL R. Gut microbiota and liver disease[J]. J Gastroenterol Hepatol,2014,29(6):1139-1148.

[9] RUNYON BA,AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis:An update[J]. Hepatology,2009,49(6):2087-2107.

[10] DUBOURG G,RAOULT D. Emerging methodologies for pathogen identification in positive blood culture testing[J]. Expert Rev Mol Diagn,2016,16(1):97-111.

[11] KROHN S,BHM S,ENGELMANN C,et al. Application of qualitative and quantitative real-time PCR,direct sequencing,and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites[J]. J Clin Microbiol,2014,52(5):1754-1757.

[12] FENG Y,CHEN CL,CHEN TH,et al. Application of nextgeneration sequencing to study ascitic microbiome in cirrhotic patients with or without spontaneous bacterial peritonitis[J]. J Microbiol Immunol Infect,2015,48(5):504-509.

[13] ENGELMANN C,KROHN S,PRYWEREK D,et al. Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival[J]. Eur J Gastroenterol Hepatol,2016,28(11):1285-1292.

[14] FAGAN KJ,ROGERS GB,MELINO M,et al. Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection[J]. PLo S One,2015,10(3):e0120642.

[15] ROGERS GB,van der GAST CJ,BRUCE KD,et al. Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension[J]. PLo S One,2013,8(9):e74884.

[16] LUTZ P,PARCINA M,BEKEREDJIAN-DING I,et al. Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin[J]. Infection,2014,42(1):175-177.

[17] SORIANO G,ESPARCIA O,MONTEMAYOR M,et al. Bacterial DNA in the diagnosis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther,2011,33(2):275-284.

[18] SANTIAGO A,POZUELO M,POCA M,et al. Alteration of the serum microbiome composition in cirrhotic patients with ascites[J]. Sci Rep,2016,6:25001.

[19] CARO E,FRANCS R,ZAPATER P,et al. Grade of soluble inflammatory response is mainly affected by circulating bacterial DNA concentrations in cirrhosis[J]. Liver Int,2016,36(10):1473-1480.

[20] SCHNABL B,BRENNER DA. Interactions between the intestinal microbiome and liver diseases[J]. Gastroenterology,2014,146(6):1513-1524.

[21] OLSZAK T,NEVES JF,DOWDS CM,et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10[J]. Nature,2014,509(7501):497-502.

[22] BIAGI E,CANDELA M,FAIRWEATHER-TAIT S,et al. Aging of the human metaorganism:The microbial counterpart[J].Age(Dordr),2012,34(1):247-267.

[23] ZEISSIG S,BLUMBERG RS. Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system[J]. FEBS Lett,2014,588(22):4188-4194.

[24] IVANOV II,HONDA K. Intestinal commensal microbes as immune modulators[J]. Cel Host Microbe,2012,12(4):496-508.

[25] CHEN Y,YANG F,LU H,et al. Characteristics of fecal microbial community in patients with cirrhosis[J]. Hepatology,2011,54(2):562-572.

[26] QIN N,LI A,FANG F,et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature,2014,513(7516):59-64.

[27] WEI X,YAN X,ZOU D,et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J]. BMC Gastroenterol,2013,13:175.

[28] BAJAJ JS,BETRAPALLY NS,GILLEVET PM. Decompensated cirrhosis and microbiome interpretation[J]. Nature,2015,525(7569):e1-e2.

[29] WOODHOUSE CA,PATEL VC,SINGANAGANM A,et al. The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment pharmacol Ther,2018,47(2):192-202.

[30] GRUMAZ S,STEVENS P,GRUMAZ C,et al. Next-generation sequencing diagnostics of bacteremia in septic patients[J]. Genome Med,2016,8(1):73.

[31] MARSTON DA,MCELHINNEY LM,ELLIS RJ,et al. Next generation sequencing of viral RNA genomes[J]. BMC Genomics,2013,14:444.

[32] LONG Y,ZHANG Y,GONG Y,et al. Diagnosis of sepsis with cell-free DNA by next-generation sequencing technology in ICU patients[J]. Arch Med Res,2016,47(5):365-371.

[33] MURTAZA M,DAWSON SJ,POGREBNIAK K,et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer[J]. Nat Commun,2015,6:8760.

[34] ROGERS GB,CUTHBERTSON L,HOFFMAN LR,et al. Reducing bias in bacterial community analysis of lower respiratory infections[J]. ISME J,2013,7(4):697-706.

[35] GOODWIN S,MCPHERSON JD,MCCOMBIE WR. Coming of age:Ten years of next-generation sequencing technologies[J]. Nat Rev Genet,2016,17(6):333-351.

施引文献

资源附件(0)

访问统计